While naïve ATF3−/− mice showed no signs of disease activity, notably, DSS-treated ATF3−/− mice developed more severe colitis with lethal disease activity leading to reduced survival rate and much shortened colon length compared to wild-type mice (Figures 3B,C, and Supplementary Figures 3A,B). Here, ATF3 is linked to colitis.